The DAWN antiviral drug trial for outpatient COVID-19 patients (DAWN)

This study aims to determine whether antiviral drugs are effective in treating symptomatic COVID-19 patients. Two antiviral drugs will be tested: camostat, a drug that has been on the market for more than 30 years in Japan and other Asian countries, and molnupiravir, an oral antiviral treatment originally developed for the treatment of influenza, which has a good safety profile. .